Oncology Pharma Inc
ONPH
OTO
Sector:
Industry:
3.60
USD
-0.03
(-0.96%)
Optionable: No Market Cap: 4 M 90-day average vol: 141,168
Previous close: 3.635 Open: 3.63 Bid: Ask:
52 week range
2.85 42.78
Last updated: Thursday 14th April 2022
Metrics
Valuation
Returns
Risk
Custom Beta One Year | 0.00 |
Custom Beta Three Years | 0.00 |
Beneish M Score | 35.70 |
Altman Z Score | 1,192.73 |
Dividends
Financial Health
Technicals
RSI (14 Day) | 38.89 |
14 Day SMA ($) | 3.73 |
14 Day EMA ($) | 3.73 |
Money Flow Index | 37.14 |
Average True Range | 0.28 |
50 Day SMA ($) | 4.32 |
200 Day SMA ($) | 10.31 |
ADX | 15.07 |
MACD | -0.17 |
Growth
Free Cash Flow QoQ Growth | 8000.00% |
Free Cash Flow YoY Growth | 26.78% |
Revenue YoY Growth | -63.99% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | -100.00% |
Chart
News
Oncology Pharma Reports on Progress with Ribera Solutions
Yahoo Finance 3/2/2022
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
Yahoo Finance 2/23/2022
Oncology Pharma Expands on Feasibility Studies and Data
Yahoo Finance 2/17/2022
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
Yahoo Finance 2/14/2022
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
Yahoo Finance 2/8/2022
Oncology Pharma's New Year Update
Yahoo Finance 1/10/2022
Oncology Pharma Meeting Towards Future Developments
Yahoo Finance 12/17/2021
Oncology Pharma slips on year-end operational update
Seeking Alpha 12/9/2021
Oncology Pharma Year End Review and Outlook
Yahoo Finance 12/9/2021
Oncology Pharma Research and Vision
Yahoo Finance 11/30/2021
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
Yahoo Finance 11/8/2021
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
Yahoo Finance 10/27/2021
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
Yahoo Finance 10/15/2021
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
Yahoo Finance 10/12/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
| NA |
|---|
| NA |
|---|
Financials
ONPH Income Statement
Annual
| Mar-02 | Mar-03 | Mar-04 | |
|---|---|---|---|
| Total revenues | 4 M | 3 M | 1 M |
| Cost of sales | 1 M | 817000 | 573000 |
| Gross operating profit | 2 M | 2 M | 527000 |
| Selling Gen & administrative expense | 4 M | 3 M | 2 M |
| Research & development expense | 773000 | 780000 | 376000 |
| Operating income | -2 M | -2 M | -2 M |
| floaterest income | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 |
| Other income net | -21000 | 85000 | 131000 |
| Pre-tax Income (EBT) | 0 | 0 | 0 |
| Income taxes | 0 | 0 | 0 |
| Net income from total operations | -2 M | -2 M | -2 M |
| Minority floaterest | 0 | 0 | 0 |
| Total net income | -2 M | -2 M | -2 M |
| Preferred dividends | 0 | 0 | 0 |
| Net income available for common | -2 M | -2 M | -2 M |
| Depreciation | 341000 | 395000 | 81000 |
| Amortization | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -2 M | -1 M | -2 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 |
| Basic EPS total | -120 | -80 | 0 |
| Diluted EPS total | -120 | -80 | 0 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!